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Background: Prognostic factors and the standard 
treatment approach for gynaecological carcinosarco-
mas have not yet been clearly defined. Although car-
cinosarcomas are more aggressive than pure epithelial 
tumours, they are treated similarly. Serous/clear cell 
and endometrioid components may be predictive fac-
tors for the efficacy of adjuvant chemotherapy (CT) 
or radiotherapy (RT) or RT in patients with uterine 
and ovarian carcinosarcomas. Heterologous carcino-
sarcomas may benefit more from adjuvant CT.
Aims: We aimed to define the prognostic and predic-
tive factors associated with treatment options in ovar-
ian (OCS) and uterine carcinosarcoma (UCS).
Study Design: Retrospective cross-sectional study
Methods: We retrospectively reviewed the medical re-
cords of patients with ovarian and uterine carcinosar-
coma from 2000 to 2013, and 127 women were includ-
ed in this study (24 ovarian and 103 uterine). Patients 
admitted to seventeen oncology centres in Turkey be-
tween 2000 and December 2013 with a histologically 
proven diagnosis of uterine carcinosarcoma with FIGO 
2009 stage I-III and patients with sufficient data ob-
tained from well-kept medical records were included 
in this study. Stage IV tumours were excluded. The pa-
tient records were retrospectively reviewed. Data from 
104 patients were evaluated for this study.
Results: Age (≥70 years) was a poor prognostic factor 
for UCS (p=0.036). Pelvic±para aortic lymph node dis-
section did not affect overall survival (OS) (p=0.35). 
Macroscopic residual disease was related with OS 
(p<0.01). The median OS was significantly longer 
in stage I-II patients than stage III patients (p=0.03). 
Adjuvant treatment improved OS (p=0.013). Adju-
vant radiotherapy tended to increase the median OS 
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Carcinosarcomas are rare gynecological tumors; approximate-
ly 2-5% of all uterine and ovarian cancers are carcinosarcomas. 
Primary peritoneal, vaginal and vulvar carcinosarcomas are ex-
tremely rare tumors. Carcinosarcomas are composed of carcino-
matous and sarcomatous components. The subtypes are defined 
as homologous (the presence of sarcomatous component originat-
ing from the mesenchymal content of the primary tumor location) 
and heterologous (the presence of sarcomatous component not 
originating from the mesenchymal content of the primary tumor 
location) according to the sarcomatous component (1). Histoge-
netic analyses indicated that these tumors originate from epithelial 
tissue; however, the characteristics and course of the disease are 
different from epithelial tumors (2,3). Gynecological carcinosar-
comas are highly aggressive neoplasms with poor prognosis (4,5). 
In previous studies, various prognostic factors have been defined; 
however, there is no consensus about these factors. Treatment 
approaches have not been clearly identified for epithelial uterine 
cancers. The predictive factors for response to treatment are also 
not known. However, data about uterine carcinosarcoma, due to 
the rarity of these tumors, are based on retrospective experiences 
rather than prospective studies. The number of patients was low 
in the published studies. In this multicenter retrospective analysis, 
we aimed to define the clinical features and prognostic and predic-
tive factors for treatment options with a larger sample size. The 
most important difference from the published studies are that it 
was a multicenter study, had a larger sample size, more treatment 
modalities and comparable primary origins.
MATERIALS AND METHODS
The present study was designed as a retrospective analysis of 
a primary uterine and ovarian carcinosarcoma patient cohort. Pa-
tients admitted to seventeen oncology centers between 2000 and 
December 2013 with a histologically proven diagnosis of uter-
ine carcinosarcoma with FIGO 2009 stage I-III and patients with 
sufficient data obtained from well-kept medical records were in-
cluded in this study. Stage IV tumors were excluded. The patient 
records were retrospectively reviewed after approval of the study 
by the University Ethical Committee. Data from 104 patients 
were evaluated for this study. Data were collected from the cen-
ters with an online standardized form. 
Patient data including age at diagnosis, parity, menopausal 
status, the date of diagnosis, the date and location of disease 
recurrence, the death date or the last contact date, the applied 
surgical procedure, lymph node dissection, and the epitheli-
al and sarcomatous components of the tumor were recorded 
from patient charts. 
Macroscopic residual disease was defined as the presence of 
≥2 cm of tumor remnant after surgery. Post-surgical treatment 
was recorded as observation (OBS), radiotherapy (RT) alone 
(brachytherapy, whole pelvic, or combination), chemotherapy 
(CT) alone and radio-chemotherapy (RCT) (concomitant, se-
quential). 
Statistical methods
Normally distributed numerical data were tested with the 
one-sample Kolmogorov-Smirnov test. Numeric variables 
with normal distribution were compared with Student’s t-test, 
and those that were not normally distributed were compared 
with the Mann-Whitney U test. Categorical variables were 
compared using the chi-squared test. Overall survival (OS) 
was accepted as the period from diagnosis to death. The sur-
vival estimates were calculated using the Kaplan-Meier meth-
od, and survival estimates between groups were compared 
with the log-rank test. Statistical analysis was performed us-
ing SPSS 20.0 (SPSS; IBM Corp.; New York, USA). A p value 
of <0.05 was considered to indicate statistical significance. 
Factors that had a p value of ≤0.15 in the univariate analysis 
were examined in the multivariate analysis (Cox regression).
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(p=0.075). However, this tendency was observed in 
UCS (p=0.08) rather than OCS (p=0.6).Adjuvant che-
motherapy had no effect on OS (p=0.15).Adjuvant ra-
diotherapy significantly prolonged the median OS in 
patients with endometrioid component (p=0.034). A 
serous/clear cell component was a negative prognostic 
factor (p=0.035). Patients with serous/clear cell his-
tology for whom adjuvant chemotherapy was applied 
had significantly longer OS (p=0.019), and there was 
no beneficial effect of adjuvant radiotherapy (p=0.4). 
Adjuvant chemotherapy was effective in heterologous 
tumours (p=0.026). In multivariate analysis, the stage 
and chemotherapy were prognostic factors for all pa-
tients. Age was an independent prognostic factor for 
UCS. However, serous/clear cell histology and radio-
therapy tended to be significant prognostic factors.
Conclusion: The primary location, the histological 
type of sarcomatous and the epithelial component 
may be predictive factors for the efficacy of chemo-
therapy or radiotherapy in UCS and OCS. 
Keywords: Carcinosarcoma, ovary, uterine, predic-
tive factors, prognostic factors
RESULTS
One hundred and twenty seven women were eligible for 
the study. The median age was 61 (range 26-85) years. One 
hundred and nine (86%) of the patients were postmenopausal, 
and 103 (81.1%) women had uterine carcinosarcoma (UCS) 
(94 corpus uteri + eight cervix uteri + one vaginal carcinosar-
coma). The sarcomatous component was homologous in 50 
(39.4%) patients and heterologous in 54 (52.5%) patients. The 
sarcomatous component was not reported in the pathology re-
ports of twenty-three (18.1%) patients. Leiomyosarcoma was 
the most common sarcomatous component in the UCS; the 
second most common sarcomatous component was rhabdo-
myosarcoma. The most common epithelial component in the 
UCS were serous papillary carcinoma and endometrioid carci-
noma, respectively. The demographic and clinical features of 
the patients are presented in Table 1.
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  Ovary Uterine  p
Age  58±12 62±11 0.10
Parity  3 4 0.19
Menopause status
 Premenopausal 6 12
 Postmenopausal 18 91 
0.11
Subtype
 Heterologous 13 37
 Homologous 10 44 0.054
 Unknown 1 22 
Epithelial subtypes
 Mucinous 1 2
 Serous 13 16
 Clear cell 1 5 
0.007
 Endometrioid 4 39
 Squamous 1 8
 Undifferentiated 1 5
 Unknown 3 28 
Sarcomatous subtypes
 Stromal sarcoma 0 2
 Leiomyosarcoma 2 24
 Undifferentiated  5 11
 Chondrosarcoma 6 (12)* 8(16)*
 Rhabdomyosarcoma 0 (6)* 9 (17)* 
0.044
 Liposarcoma 0 2
 Fibrosarcoma 1 3
 MFH 0 3
 Biphenotypic 6 8
 Unknown  4 30 
Mean tumor diameter 12.5 ±19.7 cm 6.5±3.4 cm 0.18
Stage
 I 6 46
 II 4 13 0.19
 III 14 44 
ECOG status
 0 10 33
 1 20 59
 2 2 10 0.12
 3 2 1
 4 - - 
MFH: malign fibrous histiositosarcoma
TABLE 1. The demographical, clinical and pathological features of ovarian and 
uterine carcinosarcomas
   Univariate analysis           Multivariate analysis
  Ovarian Uterine Overall  Uterine Overall
Age  




0.2 0.28 0.26 - -
Postmenopausal
Surgery 
 LND 0.31 0.65 0.75 - -
 No LND
Stage 
 I-II 0.008 0.27 0.03 - 0.05
 III
Epithelial subtype 
Endometrioid 0.33 0.36 0.26 - -
Nonendometrioid 
Epithelialsubtype
Serous/clear 0.5 0.035 0.033 0.071 0.088
Non-serous/clear
Sarcomatous subtype 
Heterolog 0.35 0.5 0.62 - -
Homolog
Residual tumor 0.021 0.12 0.01 0.72 0.24
Chemotherapy 0.9 0.12 0.15 1.4 0.041
Radiotherapy 0.6 0.08 0.075 0.058 0.36
LND: lymph node dissection
TABLE 2. Prognostic factors for ovarian and uterine carcinosarcomas
The median OS was 26.3 (95% CI, 17.9-34.7) months. 
Menopausal status was not a prognostic factor. Advanced age 
(<70 years vs. ≥ 70 years) was found to be a prognostic factor 
(Table 2).
One hundred and twenty-three patients underwent surgery. 
The surgical procedures are summarized in Table 3. The OS 
was similar in patients who underwent pelvic ± Para aortic 
lymph node dissection and in patients who did not undergo 
lymph node dissection (p=0.75). Macroscopic residual disease 
after surgery was significantly related with OS [32.5 (95% 
CI, 11.1-27.8) months vs. 19.5 (95% CI, 23.9-41.2) months, 
p=0.003].
Patients with stage I and stage II were evaluated together 
because five of the seventeen patients in stage II had died. 
The OS was longer for patients with stage I-II compared to 
patients with stage III (p=0.03). Stage III OCS patients had 
poorer survival than stage III UCS patients, although Stage 
I-II OCS patients had better OS results than the stage I-II UCS 
patients (p=0.005, Figure 1).
Patients who underwent adjuvant treatment had longer 
median OS than patients who did not [32.5 (95% CI, 23.3-
41.8) months vs. 18.3 (95% CI, 3.9-32.7 months), p=0.013] 
(Figure 2a). 
Adjuvant RT was applied in 54 of 127 patients. Adjuvant RT 
had a tendency to increase the median OS [32.5 (95% CI, 23.6-
41.5) months vs. 20.7 (95% CI, 12.2-29.1) months, P=0.075]. 
However, this tendency was more prominent in UCS patients 
(p=0.08) compared to OCS patients (P=0.6).
Adjuvant chemotherapy (89.2% platinum based) was given 
to 83 of 127 patients. Adjuvant chemotherapy had no impact 
on the median OS (p=0.15) in univariate analysis. Patients 
with UCS and OCS who received adjuvant CT had similar OS 
(p=0.64). Adjuvant chemotherapy did not improve the median 
OS in UCS patients (p=0.12). The overall survival was only 
3.8 months in three patients with OCS who did not receive 
adjuvant chemotherapy. However, two of these patients did 
not receive chemotherapy due to post-operative complications 
and one was lost to follow up. 
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  RT   CT
 Yes No p Yes No p
Age
<70 34.7 (0-76.6) 24.0 (15.7-32.3) 0.067 25.6 (13.4-37.7) 28.5 (20.3-36.7) 0.5
≥70 27.1 (16.8-37.5) 13.9 (4.3-23.5) 0.4 27.1 (10.6-43.7) 26.3 (4.4-48.2) 0.3
Stage
I-II 40.5 (4.1-77.0) 34.6 (15.0-54.2) 0.5 33.1 (21.3-44.8) 45.6 (28.5-62.9) 0.9
III 22.3 (15.5-29.0) 18.3 (10.3-26.3) 0.2 22.8 (12.9-31.7) 12.0 (2.5-21.5) 0.001
Primary site
Ovary 30.2 (6.5-54.0) 19.4 (8.0-31.0) 0.6 20.7 (2.2-39.1) 3.8 (not reached) 0.9
Uterine 33.1 (22.0-44.1) 24.0 (15.7-32.2) 0.08 27.1 (14.2-40.1) 26.3 (20.0-32.7) 0.12
Sarcomatous subtype
Homolog 32.5 (16.8-48.3) 20.2 (11.4-28.0) 0.6 19.4 (15.6-23.3) 32.5 (18.2-46.8) 0.4
Heterolog 33.1 (24.0-42.1) 36.7 (16.5-56.8) 0.6 36.7 (31.1-42.0) 10.1 (8.7-11.5) 0.026
Epithelial subtype
Endometrioid 67.4 (29.8-105.1) 34.6 (10.3-58.9) 0.034 34.7 (19.1-50.3) 45.6 (6.1-85.2) 0.9
Non-endometrioid 27.1 (16.1-38.2) 20.2 (11.4-29.0) 0.4 25.8 (0-53.2) 22.3 (14.0-29.6) 0.064
Epithelial subtype 
Serous/clear 16.0 (14.5-17.6) 20.2 (17.0-23.5) 0.4 20.7 (12.6-28.7) 9.6 (0.4-18.8) 0.019
Non-serous/clear 40.5 (0-84.4) 25.8 (11.7-39.6) 0.053 33.5 (16.1-49.0) 32.3 (16.9-49.2) 0.3
Surgery
LND 30.2 (21.4-39.1) 18.1 (10.6-25.6) 0.082 23.1 (12.8-33.5) 26.3 (8.8-43.9) 0.2
No LND 40.5 (13.5-67.6) 25.8 (22.8-28.8) 0.4 34.6 (19.2-49.3) 25.8 (21.4-30.1) 0.6
RT: radiotherapy; CT: chemotherapy; LND: lymph node dissection
TABLE 3. Predictive factors for radiotherapy and chemotherapy in ovarian and uterine carcinosarcomas
Patients who received adjuvant RT or RCT had a longer 
median OS than patients who did not receive adjuvant treat-
ment (p=0.027 and p=0.021, respectively). The median OS of 
the patients who received adjuvant CT had a tendency to be 
longer than the patient in the OBS arm (p=0.076). The overall 
survivals for patients in the adjuvant RT, RCT and CT arms 
were similar (Figure 2b).
Numerically, the epithelial component was associated with 
the longest median OS was endometrioid histology (data not 
presented). When the patients were stratified as endometrioid 
and non-endometrioid by epithelial component, the endome-
trioid component was not a prognostic factor for both the OCS 
(p=0.33) and UCS (p=0.36) groups. Adjuvant RT significantly 
prolonged the median OS in patients with endometrioid com-
ponent (0.034) (Figure 3a). Adjuvant CT had no effect on the 
survival of patients with endometrioid component. In patients 
with non-endometrioid component, while adjuvant RT had no 
beneficial effect on survival (p=0.4) (Figure 3b), adjuvant CT 
had a tendency to be beneficial (p=0.064).
Numerically, the epithelial component associated with the 
shortest median OS was serous/clear cell histology (data not 
presented). When the patients were stratified as serous/clear 
cell and non-serous/clear cell component, serous/clear cell his-
tology was found to be a negative prognostic factor (p=0.035). 
This difference was observed in UCS patients (p=0.033) but 
not in OCS patients (p=0.5). Patients with serous/clear cell 
histology who received adjuvant CT had significantly longer 
median OS (P=0.019) (Figure 3c), and there was no beneficial 
effect of adjuvant RT (p=0.4) (Table 3). In patients with non-
serous/clear cell component, adjuvant CT had no beneficial 
effect on survival (p=0.4) (Figure 3d).
There was no relationship between the sarcomatous sub-
types and the median OS (p=0.62). The efficacy of RT was 
not similar among the sarcomatous subtypes. However, adju-
vant CT was beneficial in patients with heterologous subtypes 
(p=0.026) (Table 3).
In multivariate analysis, the disease stage and CT were inde-
pendent prognostic factors for all patients, and serous/clear cell 
histology tended to be a significant factor. Age was an indepen-
dent prognostic factor for UCS patients. Serous/clear cell histol-
ogy and RT had trends towards being significant prognostic fac-
tors (Table 2). Patients with OCS could not be evaluated with 
multivariate analysis due to the low patient and event numbers. 
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FIG. 2. a-b. Overall survivals of the patients who received adjuvant therapy and those who did not receive adjuvant therapy (a). The effect of adjuvant 
therapies on uterine and ovarian carcinosarcomas (b).
FIG. 1. Overall survivals of stage I–II and stage III patients with uterine 
and ovarian carcinosarcomas.
DISCUSSION
Prognostic factors and the standard treatment approach for 
gynecological carcinosarcomas have not yet been clearly de-
fined. Although carcinosarcomas are more aggressive than 
pure epithelial tumors, they are treated similarly. It is known 
that they are more sensitive to ifosfamide than epithelial tu-
mors and insensitive to anthracyclines compared to sarcomas 
(4,5). Erickson et al. (6) suggested that black race indepen-
dently predicts worse survival in UCS. However, the predic-
tive factors related to treatment success are not clearly de-
fined. In this current study, we aimed to define the clinical and 
pathologic features, and the prognostic and predictive factors 
related with treatment. 
Heterologous subtype and unreported sarcomatous compo-
nent occurred more frequently in UCS patients compared to 
OCS patients. The most common sarcomatous component in 
UCS patients was leiomyosarcoma, and chondrosarcoma was 
the most common sarcomatous component in OCS patients. 
The second most common sarcomatous component was rhab-
domyosarcoma for both sites. The most common epithelial 
component in OCS and UCS patients were serous papillary 
carcinoma and endometrioid carcinoma, respectively. The dis-
tributions of the epithelial components of the carcinosarcomas 
were similar to the primary pure epithelial ovarian and uterine 
tumors. These findings about the frequency of epithelial and 
sarcomatous components were similar to the results presented 
in the current literature (1,5). 
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FIG. 3. a-d. Adjuvant radiotherapy significantly prolonged the median overall survival in patients with endometrioid component (a). Adjuvant radiotherapy 
had no beneficial effect on the survival of patients with non-endometrioid component (b) Patients with serous/clear cell component who received 
adjuvant chemotherapy had significantly longer median overall survival (c). In patients with non-serous/clear cell component, adjuvant chemotherapy 





Age was not a prognostic factor for all patients. However, it 
was a prognostic factor for UCS patients. In Thasom et al. (7) 
also reported that age is a prognostic factor for UCS patients. 
In addition, Rauh-Hain et al. (8) found age to be a prognostic 
factor for OCS patients. 
In the current study, the stage was one of the most important 
prognostic factors. The prognostic effect of the stage was more 
prominent in OCS patients. At an early stage, OCS patients had 
a more favorable prognosis compared to stage I-II UCS pa-
tients; however, at stage III, UCS patients tended to have worse 
prognosis. Similar to our findings, Garg et al. (9) found that 
patients with localized OCS have longer survival, although this 
finding was not statistically significant, compared to patients 
with localized UCS (129 months vs. 82 months, p=0.11); how-
ever, patients with OCS have significantly poor survival out-
comes for regional disease (18 months vs. 28 months, p=0.03) 
and distant disease (10 months vs. 14 months, p=0.001). 
Although endometrioid component was not a prognostic fac-
tor, it appeared to be a predictive factor for the efficacy of RT. 
Moreover, in both the univariate and multivariate analyses of 
UCS patients, CT did not appear to be an efficient treatment. 
Uterine carcinosarcoma patients with serous/clear cell compo-
nent have poor prognosis. Athavale et al. (10) reported serous 
element as a poor prognostic factor for OCS patients. George et 
al. (11) reported that among the histological features of UCS, 
the epithelial tumor could influence the clinical course. In the 
current study, patients with serous/clear cell component who 
received CT had significantly better survival. These findings 
suggest that, similar to the most commonly seen pure epithelial 
uterine tumors, patients with UCS may benefit from RT or CT 
differently according to their epithelial components.
Although heterologous carcinosarcomas were reported as 
a negative prognostic factor in many studies, sarcomatous 
subtypes were not found to be a prognostic factor in others 
(2,3,12-15). In this study, we also did not find sarcomatous 
subtypes to be a prognostic factor. The effect of RT was simi-
lar for the different sarcomatous subtypes. However, CT was 
an efficient adjuvant therapy in heterologous carcinosarcomas 
in our study. In many studies, a relationship between sarco-
matous components and chemotherapy efficacy has not been 
shown (2,3,16). However, patient numbers in the previous 
studies were lower than our sample size.
In our study, the efficacy of adjuvant therapy has been 
demonstrated clearly. In multivariate analysis performed for 
all patients, while CT was found to be an effective treatment 
option, RT was not. For UCS patients, while RT had a sig-
nificant effect, CT did not. Our findings, rather than being 
inconsistent, suggest that the efficiency of adjuvant treat-
ment options may be related to the primary tumor location, 
and the epithelial and sarcomatous elements. In our analysis, 
RCT and CT had similar OS outcomes. Because RCT did not 
provide better median OS in UCS patients with serous/clear 
cell component, in those patients, CT could be efficient at all 
stages whereas RT may have a limited indication for serous 
uterine carcinoma. In a Phase III randomized EORTC study, 
it suggested that adjuvant radiotherapy reduces local recur-
rence but do not improve survival outcome in stage I-II UCS 
(17). Cantrell et al. (18) retrospectively analyzed 111 stage 
I-II UCS patients (similar to our results), and they report 
that in a multivariate analysis, adjuvant CT had better PFS 
(p=0.003) and OS (p=0.058) than RT. Their findings were 
similar to ours. Tanner et al. found that patients with stage 
III-IV UCS who underwent cytoreductive surgery and an ap-
plication of CT plus RT did not have a survival advantage 
over CT alone. However, these studies did not stratify their 
analyses according to histological subtypes.
In this study, patients who underwent pelvic ± paraaortic 
lymph node dissection and patients who did not had similar 
OS. Patients with macroscopic residual disease after surgery 
had significantly worse OS. Tanner et al. (19) showed that 
complete resection followed by adjuvant treatment is the most 
important predictor for OS in patients with stage III-IV UCS. 
Doo et al. (20) reported that the degree of surgical cytoreduc-
tion is related to survival outcome and longest PFS and OS are 
achieved by non-visible disease after upfront surgical treat-
ment in OCS. Similarly, we showed that complete resection 
was associated with improved survival on OCS patients in 
our previous study (15). Moreover, the absence of a relation-
ship between the surgical procedure and OS is noteworthy. 
Together with this finding, the survival outcomes of patients 
receiving RCT are no better than patients receiving RT or 
chemotherapy alone; indicating that aggressive treatment ap-
proaches may not lead to better outcomes. In gynecological 
CS, to avoid post-surgical macroscopic residual disease, neo-
adjuvant CT may be a preferential treatment option. 
Our study has some limitations. First, the data were gath-
ered from different centers using different RT and CT proto-
cols. Due to the low number of patients, the different RT and 
CT protocols could not be analyzed. The lack of standardized 
surgery is another important weakness of this study. Adjuvant 
therapy options were not standardized among centers and 
were individual. In this multi-institutional study, centralized 
pathology review would be important and would improve the 
impact of our finding.
In conclusion, gynecological carcinosarcomas have differ-
ent clinical and prognostic features according to their primary 
location. The serous/clear cell component of carcinosarco-
mas is a prognostic factor. Serous/clear cell and endometrioid 
components may be predictive factors for the efficacy of adju-
vant CT or RT in patients with uterine and ovarian carcinosar-
comas. Heterologous carcinosarcomas may benefit more from 
adjuvant CT. To the best of our knowledge, this current study 
is the first to report that epithelial and sarcomatous compo-
nents are predictive factors for RT and CT.
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